Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
